Deven V Parmar, MD, FCP
Zydus Therapeutics Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Deven V Parmar, MD, FCP as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:55 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05045482 · Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseZydus Therapeutics Inc. · recruiting · Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease · study director
- Ph2NCT05011305 · Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisZydus Therapeutics Inc. · completed · Nonalcoholic Steatohepatitis, Fibrosis · study director
- Ph1NCT04045769 · A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersZydus Therapeutics Inc. · completed · Healthy · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.